文献速递头颈部肿瘤放疗

老年头颈部鳞状细胞癌根治性放化疗中不同化疗方案的多中心评估

A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-10-31

SENIOR 国际多中心队列研究纳入 697 例≥65 岁头颈部鳞状细胞癌患者,分析根治性放疗同步化疗方案与生存的关系。与单药顺铂相比,卡铂方案无进展生存期缩短、局部区域失败发生率更高,总生存期相近;单药与多药顺铂方案肿瘤学结局无差异。累积顺铂剂量≥200 mg/m2 与总生存期、无进展生存期改善及局部区域失败减少相关,多因素分析中仍为独立预后因素。

要点

  • 与单药顺铂相比,卡铂方案的无进展生存期更差(HR 1.39,95%CI 1.03-1.89;P<.05),局部区域失败发生率更高(亚分布 HR 1.54,95%CI 1.00-2.38;P=.05),总生存期相近(HR 1.15,95%CI 0.80-1.65;P=.46)。
  • 单药与多药顺铂方案之间所有肿瘤学结局均无显著差异(所有 P>.05)。
  • 累积顺铂剂量≥200 mg/m2 与总生存期改善(HR 0.71,95%CI 0.53-0.95;P=.02)、无进展生存期改善(HR 0.66,95%CI 0.51-0.87;P=.003)及局部区域失败发生率降低(亚分布 HR 0.50,95%CI 0.31-0.80;P=.004)相关。

核心结论

  • 对于能够耐受顺铂的老年头颈部鳞状细胞癌患者,单药顺铂可考虑作为标准化疗方案。
  • 累积顺铂剂量在老年头颈部鳞状细胞癌患者中具有预后相关性。

研究设计与样本

  • SENIOR 研究是一项国际多中心队列研究,纳入在美国和欧洲 13 个学术中心接受根治性放疗的≥65 岁头颈部鳞状细胞癌患者。
  • 本分析纳入 697 例接受同步放化疗的患者,中位年龄 71 岁。
  • 采用 Kaplan-Meier 法分析总生存期和无进展生存期,采用 Fine-Gray 竞争风险回归分析局部区域失败和远处转移发生率。

主要发现

  • 单药顺铂是最常见方案(n=310;44%),其次为顺铂联合 5-氟尿嘧啶(n=137;20%)、卡铂(n=73;10%)、丝裂霉素 C 联合 5-氟尿嘧啶(n=64;9%)。
  • 与单药顺铂相比,卡铂方案与无进展生存期缩短相关(HR 1.39,95%CI 1.03-1.89;P<.05),局部区域失败发生率更高(亚分布 HR 1.54,95%CI 1.00-2.38;P=.05),总生存期相近(HR 1.15,95%CI 0.80-1.65;P=.46)。
  • 单药与多药顺铂方案之间所有肿瘤学结局均无显著差异(所有 P>.05)。
  • 顺铂中位累积剂量为 180 mg/m2(四分位距 120-200 mg/m2)。
  • 累积顺铂剂量≥200 mg/m2 与总生存期改善(HR 0.71,95%CI 0.53-0.95;P=.02)、无进展生存期改善(HR 0.66,95%CI 0.51-0.87;P=.003)及局部区域失败发生率降低(亚分布 HR 0.50,95%CI 0.31-0.80;P=.004)相关。

关键数值与推荐

  • 与单药顺铂相比,卡铂方案的无进展生存期 HR 1.39(95%CI 1.03-1.89;P<.05),局部区域失败亚分布 HR 1.54(95%CI 1.00-2.38;P=.05),总生存期 HR 1.15(95%CI 0.80-1.65;P=.46)。
  • 累积顺铂剂量≥200 mg/m2 与总生存期 HR 0.71(95%CI 0.53-0.95;P=.02)、无进展生存期 HR 0.66(95%CI 0.51-0.87;P=.003)、局部区域失败亚分布 HR 0.50(95%CI 0.31-0.80;P=.004)相关。
  • 多因素分析中累积顺铂剂量对总生存期的 HR 为 0.996(95%CI 0.993-0.999;P=.009)。

临床怎么用

  • 作者认为,对于能够耐受顺铂的老年头颈部鳞状细胞癌患者,单药顺铂可考虑作为标准化疗方案。
  • 原文未据此给出关于累积顺铂剂量阈值的推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The number of older adults with head and neck squamous cell carcinoma (HNSCC) is increasing, and treatment of these patients is challenging. Although cisplatin-based chemotherapy concomitantly with radiation therapy is considered the standard regimen for patients with locoregionally advanced HNSCC, there is substantial real-world heterogeneity regarding concomitant chemotherapy in older patients with HNSCC. METHODS AND MATERIALS: The SENIOR study is an international multicenter cohort study including older patients (≥65 years) with HNSCC treated with definitive radiation therapy at 13 academic centers in the United States and Europe. Patients with concomitant chemoradiation were analyzed regarding overall survival (OS) and progression-free survival (PFS) via Kaplan-Meier analyses. Fine-Gray competing risk regressions were performed regarding the incidence of locoregional failures and distant metastases. RESULTS: Six hundred ninety-seven patients with a median age of 71 years were included in this analysis. Single-agent cisplatin was the most common chemotherapy regimen (n = 310; 44%), followed by cisplatin plus 5-fluorouracil (n = 137; 20%), carboplatin (n = 73; 10%), and mitomycin C plus 5-fluorouracil (n = 64; 9%). Carboplatin-based regimens were associated with diminished PFS (hazard ratio [HR], 1.39 [1.03-1.89]; P < .05) and a higher incidence of locoregional failures (subdistribution HR, 1.54 [1.00-2.38]; P = .05) compared with single-agent cisplatin, whereas OS (HR, 1.15 [0.80-1.65]; P = .46) was comparable. There were no oncological differences between single-agent and multiagent cisplatin regimens (all P > .05). The median cumulative dose of cisplatin was 180 mg/m2 (IQR, 120-200 mg/m2). Cumulative cisplatin doses ≥200 mg/m2 were associated with increased OS (HR, 0.71 [0.53-0.95]; P = .02), increased PFS (HR, 0.66 [0.51-0.87]; P = .003), and lower incidence of locoregional failures (subdistribution HR, 0.50 [0.31-0.80]; P = .004). Higher cumulative cisplatin doses remained an independent prognostic variable in the multivariate regression analysis for OS (HR, 0.996 [0.993-0.999]; P = .009). CONCLUSIONS: Single-agent cisplatin can be considered in the standard chemotherapy regimen for older patients with HNSCC who can tolerate cisplatin. Cumulative cisplatin doses are prognostically relevant in older patients with HNSCC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rühle A, Weymann M, Behrens M, et al. A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation. Int J Radiat Oncol Biol Phys. 2023. PMID: 37914144. doi:10.1016/j.ijrobp.2023.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。